Funds › Deep Track Capital, LP
Deep Track Capital, LP
13F for Q2 2026, filed Aug 14, 2026. 66 positions worth $6.9B.Managers with more than $100 million in US-listed stocks list their holdings each quarter, within 45 days of quarter end. Long positions only: no short sales or cash.
Latest report
Q2 2026
filed Aug 14, 2026
Reported value
$6.9B
+$746.9M (12.2%) vs Q1 2026
Positions
66
62 in Q1 2026
Top 10 share
39.6%
of reported value
CheckedEach line's price per share is checked against other managers' reports of the same stock. Unit mix-ups are corrected. Reports no fix can rescue are left out.
Clean
prices match other managers' reports
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, what are the biggest new, added, trimmed and exited positions of Deep Track Capital, LP in the latest 13F quarter?
Using 13F.ai, how has Deep Track Capital, LP's portfolio concentration changed over the last four quarters?
Using 13F.ai, which of Deep Track Capital, LP's top holdings have also been bought by insiders recently?
Connect your AI · Plans and the 7-day free trial (card required)
Holdings, Q2 2026
Largest first. Common shares only; puts and calls are under All positions.
| # | The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here. | Filing | ||||
|---|---|---|---|---|---|---|
| 1 | GH Guardant Health, Inc. | 3.39M | $509.1M | 7.4% | +1.6% | 13F ↗ |
| 2 | IMVT Immunovant, Inc. | 9.34M | $359.9M | 5.2% | -19.0% | 13F ↗ |
| 3 | GPCR Structure Therapeutics Inc. | 4.74M | $254.4M | 3.7% | +10.8% | 13F ↗ |
| 4 | PCVX Vaxcyte, Inc. | 4.30M | $250.0M | 3.6% | Unchanged | 13F ↗ |
| 5 | ALNY Alnylam Pharmaceuticals, Inc. | 825,000 | $248.3M | 3.6% | New | 13F ↗ |
| 6 | MANE Veradermics, Incorporated | 2.00M | $245.9M | 3.6% | +300% | 13F ↗ |
| 7 | TARS Tarsus Pharmaceuticals, Inc. | 3.67M | $230.8M | 3.4% | +1.9% | 13F ↗ |
| 8 | Nuvalent Inc | 1.78M | $220.2M | 3.2% | +29.6% | 13F ↗ |
| 9 | ALKS Alkermes plc | 4.00M | $209.6M | 3.1% | +11.4% | 13F ↗ |
| 10 | OCUL Ocular Therapeutix, Inc. | 19.69M | $193.3M | 2.8% | Unchanged | 13F ↗ |
| 11 | BMRN BioMarin Pharmaceutical Inc. | 3.31M | $189.3M | 2.8% | +188% | 13F ↗ |
| 12 | NRIX Nurix Therapeutics, Inc. | 7.74M | $187.7M | 2.7% | +21.9% | 13F ↗ |
| 13 | ORKA Oruka Therapeutics, Inc. | 1.93M | $183.3M | 2.7% | -5.3% | 13F ↗ |
| 14 | ALMS Alumis Inc. | 6.35M | $178.6M | 2.6% | -6.3% | 13F ↗ |
| 15 | IONS Ionis Pharmaceuticals, Inc. | 2.20M | $174.4M | 2.5% | +12.8% | 13F ↗ |
| 16 | CMPS COMPASS Pathways Plc · ADR | 12.16M | $172.1M | 2.5% | Unchanged | 13F ↗ |
| 17 | VERA Vera Therapeutics, Inc. | 4.00M | $171.6M | 2.5% | -2.6% | 13F ↗ |
| 18 | AXSM Axsome Therapeutics, Inc. | 700,000 | $171.3M | 2.5% | -36.4% | 13F ↗ |
| 19 | GMAB Genmab A/S · ADR | 5.65M | $155.2M | 2.3% | +54.2% | 13F ↗ |
| 20 | MLTX MoonLake Immunotherapeutics | 7.00M | $136.3M | 2.0% | +9.2% | 13F ↗ |
| 21 | COAG Hemab Therapeutics Holdings, Inc. | 3.60M | $132.3M | 1.9% | New | 13F ↗ |
| 22 | TNGX Tango Therapeutics, Inc. | 4.20M | $131.3M | 1.9% | +52.7% | 13F ↗ |
| 23 | DFTX Definium Therapeutics, Inc. | 2.75M | $129.4M | 1.9% | -8.3% | 13F ↗ |
| 24 | GRAL GRAIL, Inc. | 1.83M | $125.3M | 1.8% | +6.5% | 13F ↗ |
| 25 | BCAX Bicara Therapeutics Inc. | 4.10M | $121.7M | 1.8% | +0.9% | 13F ↗ |
| 26 | MAZE Maze Therapeutics, Inc. | 3.73M | $111.4M | 1.6% | +7.3% | 13F ↗ |
| 27 | CLDX Celldex Therapeutics, Inc. | 2.94M | $109.4M | 1.6% | +129% | 13F ↗ |
| 28 | LBRX LB Pharmaceuticals Inc | 3.35M | $108.8M | 1.6% | Unchanged | 13F ↗ |
| 29 | MBX MBX Biosciences, Inc. | 1.73M | $95.6M | 1.4% | -37.2% | 13F ↗ |
| 30 | GHRS GH Research PLC | 3.33M | $89.6M | 1.3% | New | 13F ↗ |
| 31 | COGT Cogent Biosciences, Inc. | 2.00M | $77.4M | 1.1% | +100% | 13F ↗ |
| 32 | Ataibeckley Inc | 14.42M | $76.0M | 1.1% | +20.1% | 13F ↗ |
| 33 | UTHR United Therapeutics Corporation | 123,616 | $67.0M | 1.0% | New | 13F ↗ |
| 34 | AVTX Avalo Therapeutics, Inc. | 3.61M | $66.7M | 1.0% | New | 13F ↗ |
| 35 | VRDN Viridian Therapeutics, Inc. | 3.59M | $66.0M | 1.0% | +158% | 13F ↗ |
| 36 | CYTK Cytokinetics, Incorporated | 700,000 | $59.6M | 0.9% | -49.1% | 13F ↗ |
| 37 | ALT Altimmune, Inc. | 19.25M | $58.5M | 0.9% | New | 13F ↗ |
| 38 | PSNL Personalis, Inc. | 4.00M | $53.6M | 0.8% | +33.3% | 13F ↗ |
| 39 | ACRS Aclaris Therapeutics, Inc. | 9.35M | $49.4M | 0.7% | Unchanged | 13F ↗ |
| 40 | CRMD CorMedix Inc. | 6.27M | $49.3M | 0.7% | Unchanged | 13F ↗ |
| 41 | WGS GeneDx Holdings Corp. | 700,000 | $48.1M | 0.7% | New | 13F ↗ |
| 42 | HROW Harrow, Inc. | 969,000 | $41.2M | 0.6% | New | 13F ↗ |
| 43 | CRVS Corvus Pharmaceuticals, Inc. | 2.49M | $37.2M | 0.5% | Unchanged | 13F ↗ |
| 44 | SLDB Solid Biosciences Inc. | 3.57M | $35.6M | 0.5% | Unchanged | 13F ↗ |
| 45 | BEAM Beam Therapeutics Inc. | 1.00M | $34.3M | 0.5% | +21.8% | 13F ↗ |
| 46 | DYN Dyne Therapeutics, Inc. | 1.50M | $33.3M | 0.5% | -25.0% | 13F ↗ |
| 47 | IMMX Immix Biopharma, Inc. | 2.77M | $28.6M | 0.4% | New | 13F ↗ |
| 48 | XFOR X4 Pharmaceuticals, Inc. | 5.88M | $27.5M | 0.4% | -7.3% | 13F ↗ |
| 49 | STTK Shattuck Labs, Inc. | 3.71M | $25.7M | 0.4% | New | 13F ↗ |
| 50 | MNKD MannKind Corporation | 6.00M | $25.6M | 0.4% | New | 13F ↗ |
Showing the top 50 of 66 positions. Premium lists every position, plus puts and calls.
Changes since Q1 2026
18 new, 22 added to, 15 trimmed, 14 exited, 11 unchanged. By estimated dollars.
New positions (18)
| ALNY Alnylam Pharmaceuticals, Inc. | 825,000 | New | $248.3M |
| COAG Hemab Therapeutics Holdings, Inc. | 3.60M | New | $132.3M |
| GHRS GH Research PLC | 3.33M | New | $89.6M |
| UTHR United Therapeutics Corporation | 123,616 | New | $67.0M |
| AVTX Avalo Therapeutics, Inc. | 3.61M | New | $66.7M |
| ALT Altimmune, Inc. | 19.25M | New | $58.5M |
| WGS GeneDx Holdings Corp. | 700,000 | New | $48.1M |
| HROW Harrow, Inc. | 969,000 | New | $41.2M |
| IMMX Immix Biopharma, Inc. | 2.77M | New | $28.6M |
| STTK Shattuck Labs, Inc. | 3.71M | New | $25.7M |
Added to (22)
| MANE Veradermics, Incorporated | 2.00M | +300% | $184.4M |
| BMRN BioMarin Pharmaceutical Inc. | 3.31M | +188% | $123.5M |
| CLDX Celldex Therapeutics, Inc. | 2.94M | +129% | $61.6M |
| GMAB Genmab A/S · ADR | 5.65M | +54.2% | $54.6M |
| Nuvalent Inc | 1.78M | +29.6% | $50.3M |
| TNGX Tango Therapeutics, Inc. | 4.20M | +52.7% | $45.3M |
| VRDN Viridian Therapeutics, Inc. | 3.59M | +158% | $40.4M |
| COGT Cogent Biosciences, Inc. | 2.00M | +100% | $38.7M |
| NRIX Nurix Therapeutics, Inc. | 7.74M | +21.9% | $33.8M |
| GPCR Structure Therapeutics Inc. | 4.74M | +10.8% | $24.7M |
Trimmed (15)
| AXSM Axsome Therapeutics, Inc. | 700,000 | -36.4% | -$97.9M |
| IMVT Immunovant, Inc. | 9.34M | -19.0% | -$84.2M |
| CYTK Cytokinetics, Incorporated | 700,000 | -49.1% | -$57.4M |
| MBX MBX Biosciences, Inc. | 1.73M | -37.2% | -$56.6M |
| IMCR Immunocore Holdings plc · ADR | 311,218 | -83.9% | -$51.5M |
| ALMS Alumis Inc. | 6.35M | -6.3% | -$11.9M |
| DFTX Definium Therapeutics, Inc. | 2.75M | -8.3% | -$11.8M |
| DYN Dyne Therapeutics, Inc. | 1.50M | -25.0% | -$11.1M |
| ORKA Oruka Therapeutics, Inc. | 1.93M | -5.3% | -$10.3M |
| ENTA Enanta Pharmaceuticals, Inc. | 1.44M | -26.2% | -$7.5M |
Exited (14)
| Apellis Pharmaceuticals Inc | 4.53M | Exited | -$182.3M |
| Centessa Pharmaceuticals plc ADR | 3.16M | Exited | -$125.4M |
| BBIO BridgeBio Pharma, Inc. | 841,445 | Exited | -$62.5M |
| Terns Pharmaceuticals Inc | 1.07M | Exited | -$56.6M |
| GERN Geron Corporation | 31.72M | Exited | -$47.3M |
| ANIP ANI Pharmaceuticals, Inc. | 600,000 | Exited | -$46.1M |
| Soleno Therapeutics Inc | 1.08M | Exited | -$36.1M |
| Engene Holdings Inc | 4.38M | Exited | -$29.8M |
| Apogee Therapeutics Inc | 285,000 | Exited | -$24.0M |
| JANX Janux Therapeutics, Inc. | 1.19M | Exited | -$16.5M |
The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.
All positions
Search, sort and filter every position, with puts and calls on their own tab. Premium plan.
Every position, puts and calls. Part of Premium.
Compare two quarters
Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.
Any two quarters side by side. Part of Premium.
Reported value by quarter
Value and number of positions at the end of each quarter.
Loading…
Largest positions in earlier quarters
Pick a quarter to see what the fund's biggest positions were then.
Loading…
Ten largest positions
By value, Q2 2026.
Filings
Most recent first, up to 80. An amendment can replace a report or add holdings to it. All 13F filings
Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer